Sarepta Therapeutics Inc. (SRPT) VP Sells $1,750,000.00 in Stock
Sarepta Therapeutics Inc. (NASDAQ:SRPT) VP Jayant Aphale sold 35,000 shares of the business’s stock in a transaction on Monday, September 19th. The stock was sold at an average price of $50.00, for a total value of $1,750,000.00. Following the completion of the sale, the vice president now directly owns 21,490 shares in the company, valued at $1,074,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) traded up 0.88% during trading on Wednesday, reaching $56.22. The company had a trading volume of 8,767,424 shares. Sarepta Therapeutics Inc. has a 52 week low of $8.00 and a 52 week high of $58.87. The company’s market capitalization is $2.69 billion. The stock’s 50-day moving average price is $29.05 and its 200-day moving average price is $21.62.
Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the consensus estimate of ($1.19) by $0.16. During the same period last year, the business posted ($0.87) EPS. On average, equities analysts expect that Sarepta Therapeutics Inc. will post ($4.17) EPS for the current fiscal year.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/sarepta-therapeutics-inc-srpt-vp-sells-1750000-00-in-stock.html
Large investors have recently made changes to their positions in the company. National Planning Corp increased its stake in shares of Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock valued at $242,000 after buying an additional 275 shares during the period. Rhumbline Advisers increased its stake in shares of Sarepta Therapeutics by 1.6% in the second quarter. Rhumbline Advisers now owns 46,719 shares of the company’s stock valued at $891,000 after buying an additional 721 shares during the period. Teacher Retirement System of Texas increased its stake in shares of Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock valued at $115,000 after buying an additional 724 shares during the period. First Allied Advisory Services Inc. increased its stake in shares of Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock valued at $245,000 after buying an additional 800 shares during the period. Finally, LGL Partners LLC increased its stake in shares of Sarepta Therapeutics by 4.2% in the first quarter. LGL Partners LLC now owns 24,862 shares of the company’s stock valued at $485,000 after buying an additional 1,000 shares during the period. Institutional investors and hedge funds own 72.09% of the company’s stock.
SRPT has been the topic of a number of research analyst reports. Cowen and Company reaffirmed a “market perform” rating on shares of Sarepta Therapeutics in a report on Monday, August 15th. Janney Montgomery Scott raised Sarepta Therapeutics from a “neutral” rating to a “buy” rating and upped their price target for the company from $30.00 to $65.00 in a report on Monday. Jefferies Group reiterated an “underperform” rating and set a $7.00 price objective on shares of Sarepta Therapeutics in a research report on Saturday, June 25th. Robert W. Baird reiterated an “outperform” rating and set a $23.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, July 18th. Finally, JMP Securities reiterated an “underperform” rating and set a $10.00 price objective on shares of Sarepta Therapeutics in a research report on Sunday, July 24th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $51.01.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.